Amplitude Vascular Systems vs Pliant Therapeutics

Side-by-side comparison of AI visibility scores, market position, and capabilities

Amplitude Vascular Systems logo

Amplitude Vascular Systems

EmergingLife Sciences & BioTech

Intravascular Lithotripsy & Calcified Artery Treatment Devices

Amplitude Vascular Systems (AVS) is a medical device company developing the Pulse IVL system — a high-frequency pulsatile pressure wave device for treating calcified peripheral artery disease; raised $75M+ total;

About

Amplitude Vascular Systems (AVS) is a medical device company headquartered in Fremont, California, founded to develop next-generation intravascular lithotripsy (IVL) technology for treating calcified peripheral artery disease (PAD). The company''s flagship product, the Pulse IVL system, delivers high-frequency pulsatile pressure waves through a catheter-based device to fracture calcium deposits in arterial walls — restoring vessel compliance and improving blood flow in patients with calcified, obstructed arteries in the legs, below-the-knee vessels, and other peripheral vascular territories. Calcified PAD is a significant and growing clinical problem, particularly in diabetic patients and the aging population, where conventional balloon angioplasty and stenting are less effective due to hard, calcified lesion morphology.

Full profile
Pliant Therapeutics logo

Pliant Therapeutics

ChallengerBioTech

Fibrotic Disease

Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.

AI VisibilityBeta
Overall Score
B62
Category Rank
#1 of 1
AI Consensus
62%
Trend
up
Per Platform
ChatGPT
54
Perplexity
60
Gemini
55

About

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.

Full profile

Key Details

Category
Intravascular Lithotripsy & Calcified Artery Treatment Devices
Fibrotic Disease
Tier
Emerging
Challenger
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Pliant Therapeutics
Fibrotic Disease

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.